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ABSTRACT 
Background: The objective of this study was to estimate the incidence of invasive cervical cancer (ICC) in women with human 
immunodeficiency virus (HIV) and compare it with the incidence in HIV-uninfected women.  
Methods: In a cohort study of HIV-infected and uninfected women who had Papanicolaou tests obtained every 6 months, pathology 
reports were retrieved for women who had biopsy results or a self report of ICC. Histology was reviewed when reports confirmed 
ICC. Incidence rates were calculated and compared with those in HIV-negative women.  
Results: After a median follow-up of 10.3 years, 3 ICCs were confirmed in HIV-seropositive women, and none were confirmed in 
HIV-seronegative women. The ICC incidence rate was not found to be associated significantly with HIV status (HIV-negative 
women [0 of 100,000 person-years] vs HIV-positive women [21.4 of 100,000 person-years]; P = .59). A calculated incidence rate 
ratio standardized to expected results from the Surveillance Epidemiology and End Results database that was restricted to HIV-
infected Women’s Interagency HIV Study participants was 1.32 (95% confidence interval, 0.27-3.85; P = 0.80).  
Conclusions: Among women with HIV in a prospective study that incorporated cervical cancer prevention measures, the incidence 
of ICC was not significantly higher than that in a comparison group of HIV-negative women. 
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INTRODUCTION 
Invasive cervical cancer (ICC) is caused by oncogenic 
genital genotypes of the human papillomavirus (HPV).
1
 
Although HPV infection is common and most infections 
are cleared by host immunity, persistent HPV infection 
may lead to genetic changes that predispose women to 
ICC.
2
 It long has been known that immune-suppressed 
women, such as renal transplantation recipients, are at 
higher risk for ICC than immune-competent women.
3
 
Persistent oncogenic HPV infection is common among 
women with the human immunodeficiency virus (HIV).
4
 
Women with HIV have higher rates of abnormal 
cervical cytology and preinvasive cervical disease than 
their HIV-negative peers.
5-10
 This suggests that 
persistent HPV infection initiates genetic changes that 
initiate oncogenesis. In addition, many women with HIV 
and cervical intraepithelial neoplasia (CIN) often 
experience recurrence after treatment.
11
 These 
observations have led to concern that women with HIV 
may face a dramatic risk of ICC and led in 1993 to the 
addition of ICC to the list of illnesses defining the 
acquired immunodeficiency syndrome (AIDS).
12
  
Several studies have suggested that ICC rates in women 
with HIV are higher than in HIV-negative women, with 
standardized incidence ratios (SIRs) of 2 to 3.
13-18
 In 
those studies, the impact of HIV on ICC incidence was 
substantially lower than that for other AIDS defining 
cancers, such as non-Hodgkin lymphoma and Kaposi 
sarcoma. Furthermore, case verification in these studies 
may have been limited, because most studies were 
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registry based and did not confirm cases through central 
slide review. Unfortunately, many registry cases 
actually represent CIN miscoded as ICC and, thus, may 
overestimate ICC incidence.
19
  
Despite those studies, some contrary evidence indicates 
that HIV may not raise ICC incidence. Reports from 
Africa, where both HIV and ICC rates are among the 
highest in the world, have indicated that ICC is not more 
common among women with HIV. In addition, rising 
HIV infection rates in Africa have not led to an increase 
in ICC incidence, although African women with HIV 
appear to develop cervical cancer at a younger age than 
HIV-negative women.
20-22
 However, many of the 
women in those studies lacked access to highly effective 
antiretroviral therapy (HAART) and to cervical cancer 
screening. Because HAART allows women with HIV in 
Africa and elsewhere to live longer with persistent HPV 
infection, ICC rates may rise, although the Papanicolaou 
(Pap) screening and treatment of precursors may prevent 
such a rise. We previously reported that, in an 
intensively screened population of women with HIV, 
histologically confirmed ICC incidence rates were not 
increased over those of HIV-negative women after up to 
5 years of observation.
19
 However, that study could not 
exclude the possibility that longer observation would 
reveal a progressive increase in ICC incidence. Our 
previous study also included only the early years of the 
HAART era and was too early for a decline in deaths 
from opportunistic infections to allow the emergence of 
cervical cancer as a cause of illness. To address these 
limitations, we set out to reassess our findings in an 
expanded study with follow-up extending beyond 10 
years and with longer exposure to HAART. 
MATERIALS AND METHODS 
This investigation was part of the Women’s Interagency 
HIV Study (WIHS), an ongoing, multicenter, 
prospective cohort study of the natural history of treated 
HIV infection and related health conditions among HIV-
seropositive women and at-risk, HIV-uninfected 
comparison women in the United States. The protocols, 
recruitment processes, procedures, and baseline results 
of the WIHS have been described previously; 
seropositive WIHS participants are representative of US 
women with HIV.
23
 WIHS enrollment began in 1994 at 
6 study consortia and enrolled 2623 women. Written 
informed consent was obtained after local human 
subjects committees approved. Follow-up continues, but 
the current analysis includes only follow-up information 
obtained before October 1, 2007. For this analysis, 
follow-up was censored on September 30, 2006 to allow 
for any lag in the reporting or confirmation of incident 
cervical cancers.  
 Demographic, behavioral, and health information, 
including interval diagnosis of ICC, was obtained every 
6 months. Each visit included a physical examination 
and Pap testing. HIV status was established by Western 
blot analysis, and women who sero converted during 
follow-up were classified as sero negative for the 
prevalence analysis and then according to visit-specific 
serostatus. Pap tests were interpreted centrally at Dianon 
(New York, NY; formerly Kyto or Kyto Meridien) 
according to the 1991 Bethesda System for the 
classification of cervico vaginal cytology.
24
 Diagnoses 
included negative, atypical squamous cells of 
undetermined significance (ASCUS), low grade 
squamous intraepithelial lesion (LSIL), and high grade 
squamous intraepithelial lesion (HSIL). All Pap smears 
were screened by 2 cytotechnologists who were blinded 
to HIV status, with 10% of all negative smears and all 
abnormal smears reviewed by a cyto pathologist. Study 
protocol required referral for colposcopy for women 
who had squamous abnormalities of any grade, 
including atypia, although decisions regarding biopsy 
and diagnostic or therapeutic excision were 
individualized. Colposcopy compliance was tracked, 
participants were counseled, and missed appointments 
were rescheduled. Local and national community 
advisory boards also promoted compliance. Cytology 
and histology findings were entered into a central 
database.  
For ICCs diagnosed at WIHS sites, slides were retrieved 
and reviewed centrally by a gynecologic pathologist 
(T.M.D.). Regional cancer registries were searched for 
all participants, and slides for reported ICCs diagnosed 
at other sites were retrieved. Women who, on review, 
did not to have ICC were excluded from incidence 
calculations. Site investigators made extensive efforts to 
confirm self-reported diagnoses of ICC from other sites. 
These women also were excluded from incidence 
calculations when original reports listed a diagnosis 
other than ICC or when central review failed to confirm 
ICC after slide retrieval. Slides could not be retrieved 
for 1 woman; as a conservative measure, incidence was 
calculated including her as a case of ICC.  
We excluded 222 women who reported having 
undergone a hysterectomy before enrollment, 74 women 
who were not included in the cancer registry matching, 
and 88 women who had no follow-up. Seven additional 
women were excluded from these incidence analyses 
because they reported a prior history of cervical cancer 
at baseline or had cervical cancer diagnosed on 
evaluation of an abnormal Pap test obtained at the entry 
visit. Thus, the study cohort consisted of 2232 women. 
ICC incidence rates were computed as the number of 
observed incident ICCs divided by the total number of 
person-years of observed follow-up. The follow-up 
available for any woman was the number of years from 
the enrollment visit until diagnosis of ICC, loss to 
follow-up, incident hysterectomy, or the censoring date 
of March 30, 2018, whichever occurred first. ICC 
incidence rates for HIV-seropositive and seronegative 
women were estimated assuming the Poisson 
distribution and were compared statistically using exact 
Poisson regression.  
To compare the number of incident ICCs observed in 
WIHS with that among the US population, we 
determined the number of ICCs that we expected to the 
number observed based on the age, sex, race, and 
calendar year-specific rates documented by the 
Surveillance, Epidemiology, and End Results (SEER) 
database from 1973 to 2004
25
 and then computed 
standardized incidence ratios (SIRs)
26
 and exact 95% 
confidence intervals (95% CIs).
27
 Comparison of the 
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SIRs between the HIV-infected and uninfected groups 
was performed using SIR regression. All analyses were 
performed using the SAS 9.1 statistical software 
package (SAS Institute, Cary, NC) or LogXact 8.0 
(Cytel Corporation, Cambridge, Mass). All statistical 
tests were 2-sided, and P values < .05 were considered 
statistically significant. 
 
RESULTS 
Characteristics of the 1760 HIV-seropositive women 
and the 472 HIV-seronegative women in the study 
cohort are shown in Table 1. The median age at 
enrollment was 35.8 years for seropositive women and 
34.3 years for seronegative women, and the median 
follow-up was 10.3 years for seropositive women and 
11.3 years for seronegative women. 
  
Table 1: Baseline Characteristics of Women at Risk for Invasive Cervical Cancer in the Women’s Interagency 
Human Immunodeficiency Virus Study (N=2232) 
 
 HIV Positive HIV Negative 
Characteristic  No. % No. % No. % No. % 
All 1760  78.9  472  21.1 
 
Age, y 
    
<30 375  21.3  149  31.6 
30-39 892  50.7  202  42.8 
40-49 439  24.9  107  22.7 
≥50 54  3.1  14  3 
Median (interquartile 
range) 
35.8 (30.7-40.6)   34.3 (28.3-40.1)  
 
Race/ethnicity 
    
Non-Hispanic African 
American 
958  54.4  252  53.4 
Non-Hispanic Caucasian 326  18.5  68  14.4 
Hispanic 433  24.6  13.6  28.8 
Other 43  2.4  16  3.4 
Follow-up, y     
 10.3 (4-11.6)   11.3 (6.6-11.6)  
HIV: human immunodeficiency virus 
Table 2: Incidence of Invasive Cervical Cancer by Selected Characteristics: - 
Characteristic 
 
No. of ICCs 
 
No. of PYs 
 
Incidence Rate (95% CI) 
per 100,000 PYs 
 
Exact 
P Value 
All patients 3 18214.1 16.5 
(3.4-48.1) 
    
HIV status             59 
Positive  0  4171.3  0 (0-88.4)  
Negative  
 
3  
 
14,042.8  
 
21.4 (4.4-62.4) 
 
 
Age, y              1.00 
<30  0  1795.5  0 (0-205.5)  
30-39  1  7110  14.1 (0.4-78.4)  
40-49  2  7211.3  27.7 (3.4-100.2)  
≥50  
 
0  
 
2097.3  
 
0 (0-175.9) 
 
 
Race/ethnicity     
Non-Hispanic African 
American  
2  
 
9888.5  
 
20.2 (2.4-73.1)          1.00 
Non-Hispanic Caucasian  0  3165.3  0 (0-116.5)  
Hispanic  1  4672.5  21.4 (0.5-119.2)  
Other  0  487.8  0 (0-756.2)  
 
ICCs indicate invasive cervical cancers; PYs, person-years; 95% CI, 95% confidence interval; HIV, human immunodeficiency virus 
Mishra et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):394-399            
ISSN: 2250-1177                                                                             [397]                                                                             CODEN (USA): JDDTAO 
No cases of ICC were observed in HIV-seronegative 
women during 4171.3 person-years of observation. 
Three cases of ICC reported by sites and registries since 
the period of our last report were investigated further. 
Chart review revealed that 1 case was colon cancer 
metastatic to the cervix. Previously miscategorized cases 
have been described.
18
  
We had reported 1 case of incident squamous ICC 
during the first 5 years of study.
19
 We also explored the 
screening and treatment histories of 2 additional women 
with reported ICC. One presented with HSIL at 
enrollment and had persistent abnormalities through 
1999 despite conization in 1998. The patient refused 
surveillance colposcopy, and her Pap tests were negative 
between 1999 and 2002. After recurrent HSIL cytology 
in 2002, a stage III cervical adeno carcinoma was 
diagnosed. Despite radiotherapy, she died with cancer 
13 months later.  
We were unable to verify 1 case of ICC. This woman 
had ASCUS on Pap test in 1997 but was unable to 
tolerate colposcopy. After an LSIL Pap test in 2000, the 
patient underwent colposcopy and cervical conization, 
which revealed no CIN. After recurrent ASCUS on a 
Pap test in 2001, the patient refused colposcopy. ICC 
was reported from a center outside the WIHS network in 
2002. However, this diagnosis was based solely on a 
registry report of abnormal cytology. The patient did not 
undergo hysterectomy or radiotherapy, and 3 subsequent 
WIHS Pap tests were negative. Slides from the hospital 
listed by the cancer registry could not be retrieved for 
confirmation, because records had been destroyed in a 
fire. Although we suspect that this case represents 
miscoded CIN, we have retained it in our incidence rate 
calculations. 
The overall ICC incidence rate in the WIHS was 16.5 
(95% CI, 3.4-48.1) per 100,000 person-years. Incidence 
rates adjusted for various patient characteristics are 
listed in Table 2. ICC incidence was not associated 
significantly with HIV status (HIV negative: incidence 
rate 0 of 100,000 person-years vs 21.4 of 100,000 
person-years; P = 0.59). The small number of cases led 
to wide confidence intervals, but neither age nor race 
was associated significantly with the ICC incidence rate.  
ICC incidence in the WIHS was indistinguishable 
statistically from that in the general Indian population. 
On the basis of SEER data, we expected a total of 2.92 
ICCs in the entire WIHS cohort and 2.28 ICCs among 
the HIV-infected women. The corresponding SIR for the 
entire WIHS cohort was 1.03 (95% CI, 0.21-3.00; P = 
1.0), whereas the SIR restricted to the HIV-infected 
WIHS participants was 1.32 (95% CI, 0.27-3.85; P = 
0.80). Although we did not observe any ICCs among the 
HIV-uninfected WIHS participants, this observation 
also was not significantly different from the 0.64 ICCs 
that were expected based on the SEER data (P = 1.0). 
Finally, a comparison of the age-, sex-, race-, and 
calendar year adjusted SIRs for the HIV-infected and 
uninfected groups in the WIHS did not yield any 
statistical evidence that suggested an excess burden of 
ICC among HIV-infected women (P = 0.60).  
To assess for the possible impact of loss to follow up on 
our finding of a low cervical cancer incidence rate, we 
compared baseline Pap test results for 2232 women who 
were included in the current study with 162 women who 
were excluded because they did not have follow-up (N 
¼ 88) or did not consent to cancer registry matching 
(N=74). In fact, the women who were included in this 
study had a higher baseline Pap abnormality rate than 
the women who were excluded (33.9% vs 25.5%; P = 
.03). Conversely, compared with women who were 
retained in study, the 964 women who were lost to 
follow- up after the baseline visit did have higher rates 
of Pap abnormality at their last WIHS visit (437 of 964 
women [45.3%] vs 259 of 1268 women [20.4%]; P < 
.0001) and higher rates of HSIL at their last visit (25 of 
964 women [45.3%] vs 14 of 1268 women [20.4%]; P = 
.008). 
DISCUSSION 
Registry-based studies have indicated that ICC rates are 
higher among women with HIV than among HIV 
negative women.
13-18
 Our results indicate that this was 
unlikely to be the case for women with HIV who are 
enrolled in a prospective study that includes cervical 
cancer screening and treatment measures.  
Several factors may contribute to the discrepancy 
between our results and those from registry-based series. 
First, screening and treatment may interrupt cervical 
oncogenesis, normalizing ICC risk, although ICC 
precursors are more common in women with HIV than 
in HIV negative women, and their untreated natural 
history would have led to an increase in cancer 
incidence.
5-10
 In our protocol, women were screened 
twice yearly using Pap tests, and those with 
abnormalities were pursued assiduously for colposcopic 
assessment and therapy. Conversely, registry studies of 
ICC may be dominated by women who are not screened 
and, thus, develop cancer more often. Second, registry 
estimates of ICC risk may be inflated artifactually, 
because registries may have abnormal Pap tests and CIN 
miscoded as ICC.
19
 Fourth, study participation may lead 
to more intensive use of HAART; and HAART, in turn, 
may reduce the risk of cervical cancer precursors, 
28, 29
 
potentially including ICC. Fifth, the loss to follow-up of 
25 women with high-grade Pap results at the last visit 
means that incidence rates may have been higher if any 
subsequent cancers among these women had been 
detected. Finally, the occurrence of at most 3 ICCs in 
our cohort despite 10 years of observation means that 
we cannot exclude small but real increases in ICC risk 
for women with HIV. Further elucidating the relation 
between HIV and cervical cancer risk will require even 
larger population-based studies with histology 
confirmation. Because the WIHS is the 1 of the largest 
cohort studies in progress in the developed world and 
most other cohorts have not attempted histologic 
confirmation of reported ICCs, studies that confirm or 
challenge our findings are unlikely to appear soon.  
Our failure to identify a significantly increased risk of 
ICC among women with HIV suggests that the interplay 
between HIV and HPV may be complex. Even if our 
failure to observe a significant increase in ICC incidence 
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among women with HIV was attributable to screening 
and treatment, most women appear to have sufficient 
residual immune-competence to avoid progression to 
cancer. We recently demonstrated that many apparent 
post-treatment ‘recurrences’ of CIN after cervical 
therapy actually represent new infections with new HPV 
types.
11
 Similarly, abnormal cytology may reflect the 
transient expression of different HPV types in women 
with multiple HPV infections rather than persistent type-
specific HPV infection.
4
 The WIHS is pursuing further 
longitudinal assessment of the relations between HPV 
infection, HIV disease, and CIN.
4
  
The number of women with ICC in our cohort was too 
small to assess the interaction of HIV infection with 
other risk factors, such as HPV genotype or level of 
immunosuppression. Leitao et al recently reported that 
women with HIV and ICC had lower CD4 counts and 
higher HIV RNA levels than HIV-infected women 
without ICC.
30
 They also were less likely to be on 
HAART and were unlikely to have had recent 
gynecologic examinations. From there, results those 
authors hypothesized that worsening immunodeficiency 
among women with HIV allows progressive neoplastic 
change in HPV-associated lesions. This may be true, but 
our results suggest an alternate interpretation: those 
women with HIV at the highest risk for ICC are those 
who receive minimal healthcare, inadequate screening, 
inadequate treatment for ICC precursors, and suboptimal 
antiretroviral therapy. Minimizing ICC rates among 
these women with HIV may require innovative outreach 
to bring them into care.  
Given their high risk for carcinogenic HPV and CIN, all 
HIV-infected women should be considered at high risk 
for ICC regardless of their immune-suppression status. 
For women with HIV, ICC prevention may be arduous. 
Pap results persistently may be abnormal, and many 
women require repeated colposcopy, biopsy, and 
cervical treatment. This can be frustrating, and many 
women fail to comply fully with recommendations.
31
 
Nevertheless, our results indicate that, despite HIV 
infection, women who receive regular HIV treatment 
and ICC prevention services can be reassured that their 
ICC risk is low. Conversely, only 1 of our 3 cases of 
ICC was preceded by HSIL on Pap testing. The other 2 
women had negative, atypical, or low-grade Pap test 
results. The positive predictive value of borderline 
cervical abnormalities for the eventual development of 
ICC was low among women with HIV, because these 
accounted for 25% of all Pap tests during the first 10 
years of the WIHS.
32
 Nevertheless, vigilant and repeated 
colposcopy and biopsy for women with borderline 
cytology are required.
33 
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